Macroprolactin; high molecular mass forms of circulating prolactin.
Two high molecular mass forms of prolactin (PRL) in serum have been identified by gel filtration chromatography (GFC): macroprolactin (big-big PRL, > 100 kDa) and big PRL (40-60 kDa). Macroprolactin has a variable composition and structure, but is most frequently a complex of PRL and IgG, with a molecular mass of 150-170 kDa. It is formed in the circulation following pituitary secretion of monomeric PRL but has a longer half-life, and the PRL in the complex remains reactive to a variable extent in immunoassays. In the majority of subjects little or no macroprolactin can be detected in serum, but in some individuals it may be the predominant immunoreactive component of circulating PRL and the cause of apparent hyperprolactinaemia. Owing to its high molecular mass, macroprolactin appears to be confined to the intravascular compartment and much evidence indicates that it has minimal bioactivity in vivo and is not of pathological significance. Nevertheless, hyperprolactinaemia due to macroprolactin can lead to diagnostic confusion and unnecessary further investigation and treatment if it is not recognized as such. Macroprolactin is a common cause of apparent hyperprolactinaemia with some assays and it is essential that laboratories introduce screening programmes to examine samples with elevated total immunoreactive PRL for the presence of macroprolactin and determine the monomeric PRL component which is known to be bioactive in vivo. A number of screening tests have been described; that based on the precipitation of macroprolactin with polyethylene glycol has been the most widely validated and applied. The reference technique of GFC should be available for confirmation and further investigation of samples, giving equivocal results in screening tests. In comparison with macroprolactin, little is known about big PRL. It is a more consistent component of total serum PRL but rarely, if ever, the cause of hyperprolactinaemia. Further research is required into the nature of macroprolactin and big PRL, the relationships between high molecular mass forms of PRL, and their clinical significance.
Fahie-Wilson
M N
MN
Department of Clinical Biochemistry, Southend Hospital, Westcliff-on-Sea, Essex SS0 0RY, UK. mfahie-wilson@southend.nhs.uk
John
R
R
Ellis
A R
AR
D001323:Autoantibodies / Q000276:immunology; D018491:Dopamine Agonists / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology; D005260:Female; D006031:Glycosylation; D006801:Humans; D006966:Hyperprolactinemia / Q000453:epidemiology; D007074:Immunoglobulin G / Q000737:chemistry; D008597:Menstrual Cycle; D008657:Metabolic Clearance Rate; D008970:Molecular Weight; D011247:Pregnancy; D015995:Prevalence; D011388:Prolactin / Q000097:blood* / Q000737:chemistry* / Q000187:drug effects / Q000502:physiology*; D013973:Thyrotropin-Releasing Hormone / Q000378:metabolism / Q000494:pharmacology
D001323:Autoantibodies; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D007074:Immunoglobulin G; C060678:prolactin, polymeric; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin